No Prescription |
 |
 | ||
|
Norinyl 1 Generic Mestranol |
|
| ||
No Prescription » Prescription Drugs 12 » Norinyl 1 Generic Mestranol Norinyl-1 is a birth control pill commonly known as a "Combined Oral Contraceptive" that contains both an oestrogen (mestranol) and progestogen (norethisterone) hormone. Sometimes Norinyl-1 is used to help control heavy irregular or painful periods.Oral contraceptives belonging to this group produce their birth control (or contraceptive) effect by preventing ovulation (or the release of an egg from the ovary) during each menstrual cycle. Combined Oral Contraceptives also cause changes to the mucus of the cervix and the lining of the womb which contribute to the contraceptive action.If taken according to directions the combined oral contraceptives are very effective in preventing pregnancy. The failure rate of this type of contraceptive is such that for every 1 000 women using the pill for one year two will become pregnant. Buy Norinyl 1 Generic Mestranol and other Prescription Drugs 12 products online at Medstore. 5348
About Norinyl 1 Generic Mestranol: Product Type: Prescription Drugs 12 Norinyl-1 ( Generic Mestranol/Norethisterone ) Norinyl-1 (Generic Mestranol/Norethisterone) Generic Mestranol/Norethisterone 50mcg/1mg 3 x 28 Tablets Generic Mestranol/Norethisterone Norinyl-1
View more Prescription Drugs 12 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
